Linaclotide Re: Leaky gut -- new pathway found, novel drug in development

[Guest guest]

this is the med, should hit UK shelves soonThe drug is called Linaclotide and is manufactured by Ironwood Pharmaceuticals (http://www.ironwoodpharma.com/gastrointestinal.php)"Full results from two Phase III linaclotide trials involving over 1,600 patients with irritable bowel syndrome with constipation (IBS-C) presented at the European Gastroenterology Week (UEGW) congress in Stockholm""In August 2011, Ironwood and Forest submitted a New Drug Application (NDA) with the Food and Drug Administration (FDA) seeking approval to market linaclotide to IBS-C and CC patients ages 18 and older in the U.S.In September 2011, our European partner, Almirall S.A. submitted a Market Authorization Application (MAA), with the European Medicines Agency (EMA), seeking approval to market linaclotide to IBS-C patients in the E.U."sounds almost too good to be true )Natasa >> > > > > > > Stronger Intestinal Barrier May Prevent Cancer in the Rest of the Body, New> Study Suggests> > http://www.sciencedaily.com/releases/2012/02/120221212345.htm> > "It appears that the hormone receptor guanylyl cyclase C (GC-C) -- a> previously> identified tumor suppressor that exists in the intestinal tract -- plays a> key> role in strengthening the body's intestinal barrier, which helps separate> the> gut world from the rest of the body, and possibly keeps cancer at bay.> Without> the receptor, that barrier weakens.> ...> ...silencing GC-C in mice compromised the integrity of the intestinal> barrier.> It allowed inflammation to occur and cancer-causing agents to seep out into> the> body, damaging DNA and forming cancer outside the intestine, including in> the> liver, lung and lymph nodes.> > Conversely, stimulating GC-C in intestines in mice strengthened the> intestinal> barrier opposing these pathological changes.> ...> A new drug containing GC-C is now on the verge of hitting the market, but> its> intended prescribed purpose is to treat constipation.> > This study helps lays the groundwork, Dr. Waldman said, for future> pre-clinical> and clinical studies investigating GC-C's abilities beyond those treatments> in> humans, including prevention and treatment of inflammatory bowel disease and> cancer.> ...> "Now, if you want to prevent inflammation or cancer in humans, then we need> to> start thinking about feeding people hormones that activate GC-C to tighten> up> the barrier."> > Journal References:> > 1.Jieru Egeria Lin, Adam Eugene Snook, Peng Li, Arthur Stoecker,> Gilbert> Won Kim, Sullivan Magee, Vladimir Mejia , > Valentino, Terry Hyslop, Schulz, Arthur Waldman. GUCY2C> Opposes> Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal> Barrier> Integrity. PLoS ONE, 2012; 7 (2): e31686 DOI: 10.1371/journal.pone.0031686> > 2. A. Valentino, Jieru E. Lin, Adam E. Snook, Peng Li, Gilbert W.> Kim,> Glen Marszalowicz, S. Magee, Terry Hyslop, Schulz, > A.> Waldman. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.> Journal> of Clinical Investigation, 2011; 121 (9): 3578 DOI: 10.1172/JCI57925>